Received Apr 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 2P359 | — |
Shingrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 65-year-old male patient who received Herpes zoster (Shingrix) (batch number 2P359, expiry date 16-JUN-2026) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 14-SEP-2022). On 08-APR-2025, the patient received the 2nd dose of Shingrix. On 08-APR-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date:08-APR-2025 The Vaccine Administration Facility was the same as Primary Reporter. Only one lot number and expiration date were provided. The agent asked for the lot and expiration date of the first dose and the health care provider gave the ones that are registered in this report. But the agent suspected that the pharmacist might have given the data of the second dose, instead of that first dose asked. The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of vaccination schedule. The reporter consented to follow up.